Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna

Bloomberg2021-12-03

AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best. ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Jazim
2021-12-03
Jazim
Good
- Ichua:
  Keep hoping
Kaden0204
2021-12-03
Kaden0204
Great
Supermark
2021-12-03
Supermark
Like pls
- ProsperTTM:
  Sure
- Kaden0204:
  done
KeeBoonTong
2021-12-03
KeeBoonTong
Lalala
- KeeBoonTong:
  lalala
YewKhoon
2021-12-03
YewKhoon
Like pls
- Supermark:
  I
EVE123
2021-12-03
EVE123
Like pls
- YewKhoon:
  Ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1133176709?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-03 10:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133176709","market":"us","top_or_hot":-1,"title":"Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna","media":"Bloomberg","content":"<div>\n<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\n...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia\">网页链接</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSix Vaccines Show Promise as Boosters, Led by Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 10:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\n...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia","article_id":"1133176709","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133176709","pubTimestamp":1638500272,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased a","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"translate_title":"由辉瑞和莫德纳领导的六种疫苗显示出作为助推器的前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"PFE":0.9},"content_text":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\nThe results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.\nStill, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.\nIt’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.\nTheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.\nOther Vaccines\nThe other vaccines tested were from Johnson & Johnson,Cure Vac NV and Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.\nEarly results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.\n“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”\nMost of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.\nThree of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is expected to receive clearance in Europe in the coming weeks, while Valneva should get the green light from the U.K. and EU early next year.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":601836817,"gmtCreate":1638506018509,"gmtModify":1638506057052,"author":{"id":"4091925166419540","authorId":"4091925166419540","name":"Jazim","avatar":"https://static.tigerbbs.com/85de7ecb80758afc3288fc8bb7e5ef27","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4091925166419540","authorIdStr":"4091925166419540"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601836817","repostId":1133176709,"repostType":4,"repost":{"id":"1133176709","pubTimestamp":1638500272,"share":"https://www.laohu8.com/m/news/1133176709?lang=&edition=full","pubTime":"2021-12-03 10:57","market":"us","language":"en","title":"Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=1133176709","media":"Bloomberg","summary":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased a","content":"<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from&nbsp;Moderna Inc.and the&nbsp;Pfizer Inc.-BioNTech SEpartnership performing best.</p>\n<p>The results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the&nbsp;AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.</p>\n<p>Still, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.</p>\n<p>It’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.</p>\n<p>TheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.</p>\n<p>Other Vaccines</p>\n<p>The other vaccines tested were from&nbsp;Johnson &amp; Johnson,Cure&nbsp;Vac NV&nbsp;and&nbsp;Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.</p>\n<p>Early results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout&nbsp;of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.</p>\n<p>“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”</p>\n<p>Most of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.</p>\n<p>Three of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is&nbsp;expected to receive&nbsp;clearance in Europe in the coming weeks, while Valneva should&nbsp;get the green light&nbsp;from the U.K. and EU early next year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSix Vaccines Show Promise as Boosters, Led by Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 10:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\n...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133176709","content_text":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\nThe results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.\nStill, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.\nIt’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.\nTheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.\nOther Vaccines\nThe other vaccines tested were from Johnson & Johnson,Cure Vac NV and Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.\nEarly results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.\n“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”\nMost of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.\nThree of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is expected to receive clearance in Europe in the coming weeks, while Valneva should get the green light from the U.K. and EU early next year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6828827,"gmtCreate":1638521099563,"gmtModify":1638521099593,"authorId":3554848762875033,"author":{"id":3554848762875033,"idStr":"3554848762875033","authorId":3554848762875033,"name":"Ichua","avatar":"https://static.tigerbbs.com/175ebc8e659de3f491645e9236066d54","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":601836817,"type":1,"supId":0,"prevId":0,"content":"Keep hoping","text":"Keep hoping","html":"Keep hoping"}],"langContent":"CN"},{"id":601147906,"gmtCreate":1638502119552,"gmtModify":1638502119690,"author":{"id":"4097384260129050","authorId":"4097384260129050","name":"Kaden0204","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4097384260129050","authorIdStr":"4097384260129050"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601147906","repostId":1133176709,"repostType":4,"repost":{"id":"1133176709","pubTimestamp":1638500272,"share":"https://www.laohu8.com/m/news/1133176709?lang=&edition=full","pubTime":"2021-12-03 10:57","market":"us","language":"en","title":"Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=1133176709","media":"Bloomberg","summary":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased a","content":"<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from&nbsp;Moderna Inc.and the&nbsp;Pfizer Inc.-BioNTech SEpartnership performing best.</p>\n<p>The results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the&nbsp;AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.</p>\n<p>Still, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.</p>\n<p>It’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.</p>\n<p>TheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.</p>\n<p>Other Vaccines</p>\n<p>The other vaccines tested were from&nbsp;Johnson &amp; Johnson,Cure&nbsp;Vac NV&nbsp;and&nbsp;Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.</p>\n<p>Early results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout&nbsp;of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.</p>\n<p>“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”</p>\n<p>Most of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.</p>\n<p>Three of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is&nbsp;expected to receive&nbsp;clearance in Europe in the coming weeks, while Valneva should&nbsp;get the green light&nbsp;from the U.K. and EU early next year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSix Vaccines Show Promise as Boosters, Led by Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 10:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\n...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133176709","content_text":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\nThe results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.\nStill, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.\nIt’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.\nTheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.\nOther Vaccines\nThe other vaccines tested were from Johnson & Johnson,Cure Vac NV and Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.\nEarly results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.\n“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”\nMost of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.\nThree of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is expected to receive clearance in Europe in the coming weeks, while Valneva should get the green light from the U.K. and EU early next year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":601144840,"gmtCreate":1638502045900,"gmtModify":1638502046061,"author":{"id":"3581636786147439","authorId":"3581636786147439","name":"Supermark","avatar":"https://static.tigerbbs.com/216b88e6021ef8dfdb8a3a1d156559d2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581636786147439","authorIdStr":"3581636786147439"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/601144840","repostId":1133176709,"repostType":4,"repost":{"id":"1133176709","pubTimestamp":1638500272,"share":"https://www.laohu8.com/m/news/1133176709?lang=&edition=full","pubTime":"2021-12-03 10:57","market":"us","language":"en","title":"Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=1133176709","media":"Bloomberg","summary":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased a","content":"<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from&nbsp;Moderna Inc.and the&nbsp;Pfizer Inc.-BioNTech SEpartnership performing best.</p>\n<p>The results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the&nbsp;AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.</p>\n<p>Still, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.</p>\n<p>It’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.</p>\n<p>TheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.</p>\n<p>Other Vaccines</p>\n<p>The other vaccines tested were from&nbsp;Johnson &amp; Johnson,Cure&nbsp;Vac NV&nbsp;and&nbsp;Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.</p>\n<p>Early results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout&nbsp;of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.</p>\n<p>“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”</p>\n<p>Most of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.</p>\n<p>Three of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is&nbsp;expected to receive&nbsp;clearance in Europe in the coming weeks, while Valneva should&nbsp;get the green light&nbsp;from the U.K. and EU early next year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSix Vaccines Show Promise as Boosters, Led by Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 10:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\n...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133176709","content_text":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\nThe results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.\nStill, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.\nIt’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.\nTheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.\nOther Vaccines\nThe other vaccines tested were from Johnson & Johnson,Cure Vac NV and Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.\nEarly results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.\n“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”\nMost of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.\nThree of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is expected to receive clearance in Europe in the coming weeks, while Valneva should get the green light from the U.K. and EU early next year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6827163,"gmtCreate":1638506610752,"gmtModify":1638506610786,"authorId":3575786148063178,"author":{"id":3575786148063178,"idStr":"3575786148063178","authorId":3575786148063178,"name":"ProsperTTM","avatar":"https://static.tigerbbs.com/567b8083c48d44e182808954c57715c4","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":601144840,"type":1,"supId":0,"prevId":0,"content":"Sure ","text":"Sure ","html":"Sure "},{"id":6826359,"gmtCreate":1638502112448,"gmtModify":1638502112538,"authorId":4097384260129050,"author":{"id":4097384260129050,"idStr":"4097384260129050","authorId":4097384260129050,"name":"Kaden0204","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":601144840,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"CN"},{"id":601148802,"gmtCreate":1638501514262,"gmtModify":1638501514433,"author":{"id":"3578717603960999","authorId":"3578717603960999","name":"KeeBoonTong","avatar":"https://static.tigerbbs.com/815864515bc02d554ba00b04f5f46a1a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3578717603960999","authorIdStr":"3578717603960999"},"htmlText":"Lalala","listText":"Lalala","text":"Lalala","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601148802","repostId":1133176709,"repostType":4,"repost":{"id":"1133176709","pubTimestamp":1638500272,"share":"https://www.laohu8.com/m/news/1133176709?lang=&edition=full","pubTime":"2021-12-03 10:57","market":"us","language":"en","title":"Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=1133176709","media":"Bloomberg","summary":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased a","content":"<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from&nbsp;Moderna Inc.and the&nbsp;Pfizer Inc.-BioNTech SEpartnership performing best.</p>\n<p>The results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the&nbsp;AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.</p>\n<p>Still, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.</p>\n<p>It’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.</p>\n<p>TheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.</p>\n<p>Other Vaccines</p>\n<p>The other vaccines tested were from&nbsp;Johnson &amp; Johnson,Cure&nbsp;Vac NV&nbsp;and&nbsp;Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.</p>\n<p>Early results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout&nbsp;of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.</p>\n<p>“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”</p>\n<p>Most of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.</p>\n<p>Three of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is&nbsp;expected to receive&nbsp;clearance in Europe in the coming weeks, while Valneva should&nbsp;get the green light&nbsp;from the U.K. and EU early next year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSix Vaccines Show Promise as Boosters, Led by Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 10:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\n...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133176709","content_text":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\nThe results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.\nStill, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.\nIt’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.\nTheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.\nOther Vaccines\nThe other vaccines tested were from Johnson & Johnson,Cure Vac NV and Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.\nEarly results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.\n“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”\nMost of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.\nThree of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is expected to receive clearance in Europe in the coming weeks, while Valneva should get the green light from the U.K. and EU early next year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6826249,"gmtCreate":1638501519745,"gmtModify":1638501519777,"authorId":3578717603960999,"author":{"id":3578717603960999,"idStr":"3578717603960999","authorId":3578717603960999,"name":"KeeBoonTong","avatar":"https://static.tigerbbs.com/815864515bc02d554ba00b04f5f46a1a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":601148802,"type":1,"supId":0,"prevId":0,"content":"lalala","text":"lalala","html":"lalala"}],"langContent":"CN"},{"id":601148363,"gmtCreate":1638501431173,"gmtModify":1638501431349,"author":{"id":"3582789465327658","authorId":"3582789465327658","name":"YewKhoon","avatar":"https://static.tigerbbs.com/6242857b5af4d220ef956ac7f3f119a2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582789465327658","authorIdStr":"3582789465327658"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601148363","repostId":1133176709,"repostType":4,"repost":{"id":"1133176709","pubTimestamp":1638500272,"share":"https://www.laohu8.com/m/news/1133176709?lang=&edition=full","pubTime":"2021-12-03 10:57","market":"us","language":"en","title":"Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=1133176709","media":"Bloomberg","summary":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased a","content":"<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from&nbsp;Moderna Inc.and the&nbsp;Pfizer Inc.-BioNTech SEpartnership performing best.</p>\n<p>The results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the&nbsp;AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.</p>\n<p>Still, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.</p>\n<p>It’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.</p>\n<p>TheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.</p>\n<p>Other Vaccines</p>\n<p>The other vaccines tested were from&nbsp;Johnson &amp; Johnson,Cure&nbsp;Vac NV&nbsp;and&nbsp;Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.</p>\n<p>Early results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout&nbsp;of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.</p>\n<p>“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”</p>\n<p>Most of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.</p>\n<p>Three of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is&nbsp;expected to receive&nbsp;clearance in Europe in the coming weeks, while Valneva should&nbsp;get the green light&nbsp;from the U.K. and EU early next year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSix Vaccines Show Promise as Boosters, Led by Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 10:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\n...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133176709","content_text":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\nThe results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.\nStill, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.\nIt’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.\nTheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.\nOther Vaccines\nThe other vaccines tested were from Johnson & Johnson,Cure Vac NV and Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.\nEarly results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.\n“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”\nMost of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.\nThree of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is expected to receive clearance in Europe in the coming weeks, while Valneva should get the green light from the U.K. and EU early next year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6826333,"gmtCreate":1638501975598,"gmtModify":1638501975634,"authorId":3581636786147439,"author":{"id":3581636786147439,"idStr":"3581636786147439","authorId":3581636786147439,"name":"Supermark","avatar":"https://static.tigerbbs.com/216b88e6021ef8dfdb8a3a1d156559d2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":601148363,"type":1,"supId":0,"prevId":0,"content":"I","text":"I","html":"I"}],"langContent":"CN"},{"id":601140979,"gmtCreate":1638501046799,"gmtModify":1638501046902,"author":{"id":"3581577028225498","authorId":"3581577028225498","name":"EVE123","avatar":"https://static.tigerbbs.com/2d9fc87245feb9cc79269f594d4cc961","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581577028225498","authorIdStr":"3581577028225498"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601140979","repostId":1133176709,"repostType":4,"repost":{"id":"1133176709","pubTimestamp":1638500272,"share":"https://www.laohu8.com/m/news/1133176709?lang=&edition=full","pubTime":"2021-12-03 10:57","market":"us","language":"en","title":"Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=1133176709","media":"Bloomberg","summary":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased a","content":"<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from&nbsp;Moderna Inc.and the&nbsp;Pfizer Inc.-BioNTech SEpartnership performing best.</p>\n<p>The results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the&nbsp;AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.</p>\n<p>Still, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.</p>\n<p>It’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.</p>\n<p>TheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.</p>\n<p>Other Vaccines</p>\n<p>The other vaccines tested were from&nbsp;Johnson &amp; Johnson,Cure&nbsp;Vac NV&nbsp;and&nbsp;Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.</p>\n<p>Early results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout&nbsp;of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.</p>\n<p>“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”</p>\n<p>Most of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.</p>\n<p>Three of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is&nbsp;expected to receive&nbsp;clearance in Europe in the coming weeks, while Valneva should&nbsp;get the green light&nbsp;from the U.K. and EU early next year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Six Vaccines Show Promise as Boosters, Led by Pfizer and Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSix Vaccines Show Promise as Boosters, Led by Pfizer and Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 10:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\n...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-12-02/six-vaccines-show-promise-as-boosters-led-by-pfizer-and-moderna?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133176709","content_text":"AU.K. studytesting seven different Covid-19 vaccines as booster doses found most of them increased antibodies, with shots from Moderna Inc.and the Pfizer Inc.-BioNTech SEpartnership performing best.\nThe results, published Thursday, tested the vaccines in more than 2,800 volunteers 30 and older who had already received two doses of the AstraZeneca Plcor Pfizer shots. All seven vaccines boosted immunity after the Astra vaccine, compared with a placebo, while six raised antibody levels after Pfizer, the study found.\nStill, there were large variations between the antibody and cellular immune responses of the different vaccines, with the biggest boosts seen from the messenger-RNA vaccines from Pfizer and Moderna. Antibody levels were measured four weeks after the booster was given.\nIt’s unclear how many doses of the vaccines will be needed to provide the longest-lasting protection, or whether yearly Covid shots will be required, but the level of antibodies induced by a number of the vaccines wanes after a few months, pushing the case for boosters. With the new omicron variant spreading, countries are looking to protect their populations as quickly as they can.\nTheValneva SEvaccine, which performed well in trials but hasn’t yet been authorized for use, was the only shot that didn’t increase antibody levels after two doses of Pfizer compared with a placebo, though the vaccine was only tested in about 100 people. The study found all seven shots were safe to use as third doses.\nOther Vaccines\nThe other vaccines tested were from Johnson & Johnson,Cure Vac NV and Novavax Inc. The shots were given 10 to 12 weeks after a second dose of either the Astra or Pfizer vaccines.\nEarly results from the study were used to inform Britain’s initial booster program in September, which was focused on older people and relied on the Pfizer and Moderna shots as third doses. The U.K.expanded the rollout of boosters to all adults this week in light of the new omicron variant, and cut the time from six months after a second dose to three.\n“These data are directly relevant to the decision-making this week,” Saul Faust, a professor of pediatric immunology and infectious diseases, and the lead investigator on the study, said at a press briefing. If a “country or region of the world only has one of the vaccines that we’ve shown that boost then that will be fine to use as a booster and safe to do it. It’s not all about mRNA.”\nMost of the vaccines also produced good T-cell responses, another arm of a person’s immune defense, though the effect of Valneva as a booster was less strong.\nThree of the vaccines haven’t yet been authorized in the U.K. or European Union. CureVacabandonedits first-generation vaccine in October after disappointing trial results. Novavax is expected to receive clearance in Europe in the coming weeks, while Valneva should get the green light from the U.K. and EU early next year.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6826231,"gmtCreate":1638501440670,"gmtModify":1638501440768,"authorId":3582789465327658,"author":{"id":3582789465327658,"idStr":"3582789465327658","authorId":3582789465327658,"name":"YewKhoon","avatar":"https://static.tigerbbs.com/6242857b5af4d220ef956ac7f3f119a2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":601140979,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":68,"commentSize":17,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133176709"}